Investors should combine low-correlated asset classes, such as equity and debt, to balance growth and stability ...

The SOXX ETF surged 41% in 2025 on AI chip demand. Explore catalysts, valuation risks, and why it’s rated BUY—read now to ...

Any investors hoping to find a Sector - Utilities fund could think about starting with Virtus Duff & Phelps Water A (AWTAX). AWTAX carries a Zacks Mutual Fund Rank of 2 (Buy), which is based on ...

Harbor International Core Fund did better than its market average this quarter through smart stock picks in Europe. Review ...

While Aether Holdings (ATHR) is still in an investment phase, its balance sheet provides significant flexibility. The company carries no debt and reports a current ratio above 11, reflecting strong ...

Stocks with betas higher than 1.0 are considered more volatile than the market, while stocks with betas lower than 1.0 are ...

Past returns often dominate mutual fund discussions, but they don’t tell the full story. Understanding risk, consistency and ...

The Supreme Court of Ghana has unanimously ruled that Alpha Beta Education Centre Limited holds valid title to parcels of ...

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Learn more about whether nLIGHT, Inc. or Mirion Technologies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The approval makes AQVESME the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, a rare blood disorder. The drug is expected ...